Earnings Call Summary | Electromed(ELMD.US) Q2 2024 Earnings Conference
Earnings Call Summary | Electromed(ELMD.US) Q2 2024 Earnings Conference
The following is a summary of the Electromed, Inc. (ELMD) Q2 2024 Earnings Call Transcript:
以下是Electromed, Inc.(ELMD)2024年第二季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Electromed's Q2 net revenue increased by 17% over the last year, reaching a record of $13.7 million.
Gross profit rose to $10.5 million or 77% of net revenues due to decreased shipping costs.
The company reported a record pre-tax income of $2.4 million and net income of $1.7 million, with earnings per share of $0.19.
Electromed has a strong financial position with $10.4 million in cash, no debt, and an increased working capital to $32.7 million.
Electromed第二季度的净收入比去年增长了17%,达到创纪录的1,370万美元。
由于运输成本下降,毛利增至1,050万美元,占净收入的77%。
该公司报告了创纪录的税前收入为240万美元,净收入为170万美元,每股收益为0.19美元。
Electromed的财务状况良好,拥有1,040万美元的现金,没有债务,营运资金增加到3,270万美元。
Business Progress:
业务进展:
Electromed plans to grow its top line and capture operating leverage from growth investments.
Focus remains on treating bronchiectasis patients with SmartVest Airway Clearance technology.
Plans to engage with key opinion leaders and societies to establish treatment guidelines for bronchiectasis patients are in progress.
The company plans to continue its sales force expansion, expecting to hire 5 additional sales reps in the second half of their fiscal year.
Electromed has signed a distribution agreement with Marathon Medical to improve product access in government facilities.
The company is rolling out the SmartAdvantage program to enhance customer service and streamline order processes.
Electromed计划增加收入,并从成长型投资中获得运营杠杆作用。
重点仍然是使用SmartVest Airway Clearing技术治疗支气管扩张患者。
与主要意见领袖和社会团体合作制定支气管扩张患者治疗指南的计划正在进行中。
该公司计划继续扩大销售队伍,预计将在本财年下半年再雇用5名销售代表。
Electromed已与Marathon Medical签署了分销协议,以改善政府机构的产品准入。
该公司正在推出SmartAdvantage计划,以增强客户服务并简化订单流程。
More details: Electromed IR
更多详情: 电磁红外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。